Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changmeng Cai

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2022
Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancerWanting Han, Mingyu Liu, Dong Han, et al.
Cancer Research|February 26, 2021
Susceptibility-Associated Genetic Variation in <i>NEDD9</i> Contributes to Prostate Cancer Initiation and ProgressionDong Han, Jude N Owiredu, Bridget M Healy, et al.
Cell Reports|December 9, 2014
Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activityChangmeng Cai, Housheng Hansen He, Shuai Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2016
ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate CancerShuai Gao, Huihui Ye, Sean Gerrin, et al.
Cancer Research|March 27, 2015
PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapyChen-Lin Hsieh, Ginevra Botta, Shuai Gao, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 7, 2023
SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1Zifeng Wang, Jessica Petricca, Mingyu Liu, et al.
Cancer Research Communications|September 4, 2023
Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer ProgressionAnna Besschetnova, Wanting Han, Mingyu Liu, et al.
ACS Chemical Biology|April 19, 2013
Discovery of a selective irreversible BMX inhibitor for prostate cancerFeiyang Liu, Xin Zhang, Ellen Weisberg, et al.
Signal Transduction and Targeted Therapy|May 1, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancerAnmbreen Jamroze, Xiaozhuo Liu, Surui Hou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptorsEddy J Chen, Adam G Sowalsky, Shuai Gao, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2022
Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancerWanting Han, Mingyu Liu, Dong Han, et al.
Cancer Research|February 26, 2021
Susceptibility-Associated Genetic Variation in <i>NEDD9</i> Contributes to Prostate Cancer Initiation and ProgressionDong Han, Jude N Owiredu, Bridget M Healy, et al.
Cell Reports|December 9, 2014
Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activityChangmeng Cai, Housheng Hansen He, Shuai Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2016
ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate CancerShuai Gao, Huihui Ye, Sean Gerrin, et al.
Cancer Research|March 27, 2015
PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapyChen-Lin Hsieh, Ginevra Botta, Shuai Gao, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 7, 2023
SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1Zifeng Wang, Jessica Petricca, Mingyu Liu, et al.
Cancer Research Communications|September 4, 2023
Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer ProgressionAnna Besschetnova, Wanting Han, Mingyu Liu, et al.
ACS Chemical Biology|April 19, 2013
Discovery of a selective irreversible BMX inhibitor for prostate cancerFeiyang Liu, Xin Zhang, Ellen Weisberg, et al.
Signal Transduction and Targeted Therapy|May 1, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancerAnmbreen Jamroze, Xiaozhuo Liu, Surui Hou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptorsEddy J Chen, Adam G Sowalsky, Shuai Gao, et al.
Pageof 6